

FY2017 3Q Consolidated Financial Overview (IFRS based)

CHUGAI PHARMACEUTICAL CO., LTD. Vice President General Manager of Finance & Accounting Dept. Toshiaki Itagaki

October 25, 2017

FY2017 3Q Consolidated Financial Overview

Forward-Looking Statements



This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the "Company"). These statements reflect the Company's current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company's businesses.

Note: Amounts shown in this report are rounded to the nearest 0.1 billion yen Variance and % are calculated based on the amounts shown.

FY2017 3Q Consolidated Financial Overview

3Q Results Summary

INNOVATION BEYOND IMAGINATION



- Revenues: 387.6 billion yen (+26.1, +7.2% YoY)
- Domestic sales excl. Tamiflu: increase due to growth of main products exceeding impact of

HIP revision (+3.8, +1.4%)

- Overseas sales: growth of Alecensa export to Roche, etc. (+12.0, +19.4%)
- Royalties and other operating income: increase in milestone income (+8.9, +63.6%)
- Cost of sales / Operating expenses (Core basis)
- Cost of sales: the ratio to sales improved due to change in product mix, etc. (-1.8% points, from 52.7% to 50.9%)
- Operating expenses: overall increase mainly due to the increase of research and development expenses and general and administration expenses, etc. (-4.4, +3.7%)

Profits

FY2017 3Q Consolidated Financial Overview

IFRS and Core Results Jan-Sep

	IFRS results	Non-core	Non-core items			
(Billion JPY)	2017		Others	2017		
	Jan - Sep	Intangible assets	Others	Jan - Sep		
Revenues	387.6			387.6		
Sales	364.8			364.8		
Royalties and other operating income	22.9			22.9		
Cost of sales	-186.5	+0.9		-185.6		
Gross profit	201.1	+0.9		202.1		
Operating expenses	-124.9	+2.5	-1.0	-123.4		
Marketing and distribution	-49.2			-49.2		
Research and development	-65.7	+2.5		-63.2		
General and administration	-10.0		-1.0	-11.0		
Operating profit	76.2	+3.4	-1.0	78.7		
Financing costs	-0.1			-0.1		
Other financial income (expense)	-0.2			-0.2		
Other expense	-1.1			-1.1		
Profit before taxes	74.9	+3.4	-1.0	77.3		
Income taxes	-17.0	-0.9	+0.3	-17.6		
Net income	57.9	+2.5	-0.7	59.7		
Chugai shareholders	57.2	+2.5	-0.7	59.0		
Non-controlling interests	0.7			0.7		



(Billions of Non-Core items	JPY)
 Intangible assets: Amortization of intangible assets Impairment 	+0.9 +2.5
2. Others Legal income and expenses	-1.0
Core net income attributable to Chugai shareholders	59.0
(Millions of sha	ares)
Weighted average number of shares and equity securities in issue used to calculate	
diluted earnings per share	547
(JPY)
Core EPS 10	7.80

FY2017 3Q Consolidated Financial Overview

Year on Year (Core)

Financial Overview Jan - Sep



	201	6	201	7						A member of
(Billions of JPY)	Jan - S	Sep Revenues	Jan - S	Sep Revenues	Grow	<i>r</i> th				(Billions o
Revenues	361.5	veriues	387.6	revenues	+26.1	+7.2%	Dovo	Itics and s	ther operating i	n
Sales	347.5		364.8		+17.3	+5.0%	2		milestone incom	
excl. Tamiflu	339.1		354.8		+15.7	+4.6%	11		milestone mcon	le
Domestic	277.2		281.0		+3.8	+1.4%	Othe	r financial	income (expens	se)
Export to Roche	49.2		60.6		+11.4	+23.2%	E	kchange ga	ains/losses	
•									es on derivatives	
Other overseas	12.6		13.2		+0.6	+4.8%		Gains/Loss orward con	es on foreign ex tracts)	change
Tamiflu	8.4		10.0		+1.6	+19.0%			-	
Ordinary	7.3		6.3		-1.0	-13.7%	Other Expenses			
Govt. stockpiles, etc.	1.2		3.7		+2.5	+208.3%	5	Settlement	for transfer pric	ing taxation
Royalties and other operating income	14.0		22.9		+8.9	+63.6%				
Cost of sales	-183.0	50.6%	-185.6	47.9%	-2.6	+1.4%	Co		ratio vs. Sales	
Gross profit	178.6	49.4%	202.1	52.1%	+23.5	+13.2%)16 - Sep	2017 Jan – Sep
Operating expenses	-119.0	32.9%	-123.4	31.8%	-4.4	+3.7%			.7%	50.9%
Operating profit	59.6	16.5%	78.7	20.3%	+19.1	+32.0%	l			
Financing costs	-0.1		-0.1		0.0	0.0%	Ma	irket avera	ige exchange r	ate (JPY)
Other financial income (expense)	0.5		-0.2		-0.7	-			2016	2017
Other Expenses	-		-1.1		-1.1	-		4 01/5	Jan – Sep	Jan - Sep
Income taxes	-15.7		-17.6		-1.9	+12.1%		1 CHF 1 EUR	110.88	113.73 124.33
Net income	44.3	12.3%	59.7	15.4%	+15.4	+34.8%		1 USD	121.28 108.68	124.33
EPS (JPY)	79.93		107.80		+27.87	+34.9%		1 SGD	79.25	80.52

of JPY)

Royalties and other operating income			
Increase in milestone income			
Other financial income (expense)	-0.7		
Exchange gains/losses	-2.5		
Gains/Losses on derivatives (Gains/Losses on foreign exchange forward contracts)	+1.9		
Other Expenses	-1.1		
Settlement for transfer pricing taxation			

2016	2017
Jan – Sep	Jan – Sep
52.7%	50.9%

110.88	113.73
121.28	124.33
108.68	111.92
79.25	80.52

INNOVATION BEYOND IMAGINATION

IBI18 Aiming to become "Top Pharmaceutical Company"

Kadcyla (5.8)

-0.3,

%: Year-on-year percentage change

(): Actual sales in FY2017

-4.9%


FY2017 3Q Consolidated Financial Overview

Year on Year

Sales (excl. Tamiflu) Jan - Sep

Sales by Disease Area, Year on Year Comparisons

(Billions of JPY)



*Sales in transplant, immunology and infectious diseases area, which was disclosed separately until the end of FY2016, has been included in "Others" from FY2017 1Q results.



Sales by Products, Year on Year Changes **Tamiflu Sales Trends**

Aiming to become "Top Pharmaceutical Company" **IBI 18**

FY2017 3Q Consolidated Financial Overview

Innovation all for the patients CHUGAI (Roche) A member of the Roche group

Fiscal Term Sales											Season	l		
(Billions of JPY)	FY2	012	FY2	013	FY2	014	FY2	015	FY2	016	FY2	017	(from the second ha	alf of FY to
	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Sep	the first half of the	next FY)								
	7.8												2011	9.1
		2.4	8.2										2012	10.6
				1.9	7.0								2013	9.0
Ordinary						5.8	6.7						2014	12.6
Ordinary								1.5	7.3				2015	8.7
										4.7	6.3		2016	11.0
												0.0		
	10.2	(+4.8)	10.1	(-0.1)	12.9	(+2.8)	8.2	(-4.7)	12.0	(+3.8)	6.3	(-1.0)		
	•													
Govt. Stockpiles	0.4	1.5	0.8	0.1	0.1	0.1	0.0	0.0	0.0	1.5	1.9	1.8		
etc.	1.9	(-1.4)	0.9	(-1.0)	0.2	(-0.7)	0.0	(-0.2)	1.5	(+1.5)	3.7	(+2.5)		
	8.1	3.9	9.0	2.0	7.1	5.9	6.7	1.5	7.3	6.2	8.2	1.9		
Total														
	12.0	(+3.3)	11.0	(-1.0)	13.0	(+2.0)	8.2	(-4.8)	13.5	(+5.3)	10.0	(+1.6)		

() Year on year

INNOVATION BEYOND IMAGINATION

IBI18 Aiming to become "Top Pharmaceutical Company"


FY2017 3Q Consolidated Financial Overview

Year on Year (Core)

Operating Profit Jan - Sep

CHUGAI

Innovation all for the patients



		<	Roche A member of t
(Billions of JPY)	2016 Jan - Sep	2017 Jan - Sep	Growth
Revenues	361.5	387.6	+26.1
Cost of sales	-183.0	-185.6	-2.6
Gross profit	178.6	202.1	+23.5
of which Sales	164.5	179.2	+14.7
Royalties, etc.	14.0	22.9	+8.9
Marketing and distribution	-49.9	-49.2	+0.7
Research and development	-60.2	-63.2	-3.0
General and administration	-8.9	-11.0	-2.1
Operating profit	59.6	78.7	+19.1
Increase in gross profit from	sales		+14.7
Increase in export to R to sales due to change			cost of sale
Increase in royalties and oth	•		+8.9
Decrease in marketing and			+0.7
Reclassification of som	ne expenses	due to organ	izational cha
etc.			
Increase in research and de	velopment ex	penses	-3.0
Progress of projects a	nd reclassific	ation of some	e expenses
organizational change	es, etc.		
Increase in general and adm	ninistration ex	kpenses, etc.	-2.1

Increase in various expenses, including corporate enterprise tax (pro forma standard taxation)

FY2017 3Q Consolidated Financial Overview

Year on Year (Core)

Financial Overview Jul - Sep



	201		201				
(Billions of JPY)	Jul - S	•	Jul - S	•	Grow	rth	I
		Revenues	vs. F	Revenues			
Revenues	114.0		134.9		+20.9	+18.3%	_
Sales	110.2		127.9		+17.7	+16.1%	
excl. Tamiflu	109.1		126.1		+17.0	+15.6%	
Domestic	93.0		97.9		+4.9	+5.3%	i i
Export to Roche	11.8		23.7		+11.9	+100.8%	
Other overseas	4.3		4.4		+0.1	+2.3%	
Tamiflu	1.1		1.9		+0.8	+72.7%	I
Ordinary	-0.0		0.0		0.0	-	
Govt. stockpiles, etc.	1.2		1.8		+0.6	+50.0%	
Royalties and other operating income	3.8		6.9		+3.1	+81.6%	
Cost of sales	-58.5	51.3%	-64.8	<mark>48.0%</mark>	-6.3	+10.8%	-
Gross profit	55.5	48.7%	70.1	52.0%	+14.6	+26.3%	(
Operating expenses	-40.0	35.1%	-41.7	<mark>30.9%</mark>	-1.7	+4.3%	-
Operating profit	15.4	13.5%	28.5	21.1%	+13.1	+85.1%	_
Financing costs	-0.0		-0.0		0.0	0.0%	- N
Other financial income (expense)	0.2		0.0		-0.2	-100.0%	•••
Other Expenses	-		-0.7		-0.7	-	
Income taxes	-3.7		-6.9		-3.2	+86.5%	
Net income	11.9	10.4%	20.9	15.5%	+9.0	+75.6%	-
EPS (JPY)	21.49		37.70		+16.21	+75.4%	•

	Increase in gross profit from sales	+11.5
	Increase in expert to Peebo and	
8.3%	Increase in export to Roche and improvement of cost of sales ratio to	
6.1%	sales	
5.6%		
5.3%	Increase in royalties and other operating income	+3.1
0.8%	Increase in milestone income	
2.3%		
2.7%	Increase in operating expenses	-1.7
-	Increase in marketing and distribution	-0.2
0.0%	Increase in research and development Progress of projects, etc.	-0.7
1.6%	Increase in general and administration Increase in various expenses	-0.8
0 00%		

Cost of sales ratio vs. Sales

2016	2017
Jul – Sep	Jul – Sep
53.1%	50.7%

Market average exchange rate for the period
 of Jul – Sep

	2016	2017
	Jul-Sep	Jul-Sep
1CHF	104.97	115.33
1EUR	114.31	130.36
1USD	102.44	111.01
1SGD	75.75	81.57
	1EUR 1USD	Jul-Sep 1CHF 104.97 1EUR 114.31 1USD 102.44

FY2017 3Q Consolidated Financial Overview

vs. Forecast (Core)

Financial Progress Jan - Sep

(Billions of JPY)	Actual	Forecast on Feb. 1		2016	
	2017	2017	Progress	Progress *	
	Jan - Sep	Jan - Dec			
Revenues	387.6	520.5	74.5%	73.5%	
Sales	364.8	490.4	74.4%	73.5%	
excl. Tamiflu	354.8	482.2	73.6%	73.8%	С
Domestic	281.0	393.9	71.3%	73.0%	
Export to Roche	60.6	67.4	89.9%	78.3%	
Other overseas	13.2	20.9	63.2%	75.0%	
Tamiflu	10.0	8.2	122.0%	62.2%	
Royalties and other operating income	22.9	30.0	76.3%	73.3%	E
Cost of sales	-185.6	-252.0	73.7%	74.2%	
Gross profit	202.1	268.5	75.3%	72.9%	+
Operating expenses	-123.4	-176.5	69.9%	72.3%	+
Operating profit	78.7	92.0	85.5%	73.9%	
EPS (JPY)	107.80	124.11	86.9%	78.0%	



Cost of sales ratio vs. Sales

2017	2017
Jan – Sep	Jan – Dec
Actual	Forecast
50.9%	51.4%

Exchange rate (JPY)

	2017	2017
	Jan – Sep	Jan – Dec
	Actual *	Assumption
1CHF	113.73	106.00
1EUR	124.33	122.00
1USD	111.92	115.00
1SGD	80.52	80.00

* Jan – Sep progress versus Jan – Dec

* Market average exchange rate for the period of Jan – Sep.

vs. Forecast (Core)

FY2017 3Q Consolidated Financial Overview



Sales Progress (excl. Tamiflu) Jan - Sep

Roche A member of the Roche group

(Billions of IDV)	Actual	Forecast on Feb. 1		2016
(Billions of JPY)	2017 Jan - Sep	2017 Jan - Dec	Progress	Progress *
Sales excl. Tamiflu	354.8	482.2	73.6%	73.8%
Domestic	281.0	393.9	71.3%	73.0%
Oncology	163.5	230.0	71.1%	73.2%
Avastin	67.6	92.7	72.9%	73.6%
HER2 Franchise	40.1	57.5	69.7%	73.2%
Herceptin	24.6	35.1	70.1%	73.3%
Perjeta	9.8	12.9	76.0%	72.3%
Kadcyla	5.8	9.4	61.7%	73.5%
Rituxan	24.1	34.0	70.9%	72.6%
Alecensa	11.7	15.9	73.6%	68.9%
Xeloda	8.9	13.7	65.0%	74.0%
Tarceva	7.7	11.3	68.1%	73.0%
Zelboraf	0.1	0.4	25.0%	75.0%
Bone and Joint	67.1	94.5	71.0%	72.5%
Actemra	23.6	32.3	73.1%	72.2%
Edirol	21.1	29.5	71.5%	71.5%
Bonviva	6.2	9.2	67.4%	72.6%
Suvenyl	6.4	9.2	69.6%	74.2%

(Billions of JPY)	Actual	Actual Forec on Fel		2016
	2017 Jan - Sep	2017 Jan - Dec	Progress	Progress *
Renal	28.3	39.0	72.6 %	72.7%
Mircera	17.2	25.0	68.8%	71.5%
Oxarol	5.9	6.8	86.8%	74.7%
Others	22.0	30.3	72.6 %	73.9%
CellCept	6.4	9.0	71.1%	72.2%
Overseas	73.8	88.4	83.5%	77.7%
Actemra	48.7	59.4	82.0%	79.4%
Export to Roche	47.6	58.0	82.1%	79.5%
Neutrogin	9.2	11.6	79.3%	77.9%
Alecensa	10.2	9.5	107.4%	59.5%
Export to Roche	10.2	9.5	107.4%	59.5%

* Jan - Sep progress versus Jan - Dec.

FY2017 3Q Consolidated Financial Overview


vs. Forecast (Core)





FX impact Jan – Sep 2017 (Billions of JPY) (FX impact vs. Assumption) +0.9Revenues +0.3Sales +0.5Royalties and other operating income Cost of sales Cost of sales -0.8 -0.6 Expenses Operating expenses -0.5 **Operating profit**

Impact from Foreign Exchange

Actual / Forecast rate* (JPY)	2016 Jan - Sep Actual	2017 Jan -Dec Assumption	2017 Jan - Sep Actual
1CHF	110.88	106.00	113.73
1EUR	121.28	122.00	124.33
1USD	108.68	115.00	111.92
1SGD	79.25	80.00	80.52







11



Overview of Development Pipeline

CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of R&D Portfolio Management Dept., Project & Lifecycle Management Unit Minoru Hirose

October 25, 2017

(as of Oct. 25, 2017)

Projects under Development (1)

Overview of Development Pipeline

Innovation all for the patients

СНИДАІ

Roche A member of the Roche group

	Phase I	Phase II	Pha	se III	Filed
Oncology	CKI27 (Japan / overseas) - solid tumors RG7596 / polatuzumab vedotin - NHL RG7604 / taselisib - solid tumors GC33 (RG7686) / codrituzumab - HCC★ ERY974 (overseas) - solid tumors RG7421 / cobimetinib - solid tumors		RG1273 / Perjeta - gastric cancer RG3502 / Kadcyla - breast cancer (adjuvant) RG435 / Avastin - RCC RG7440 / ipatasertib - prostate cancer	RG7446 / atezolizumab - NSCLC (adjuvant) - SCLC - urothelial carcinoma - MIUC (adjuvant) - RCC - RCC (adjuvant) - breast cancer - ovarian cancer - prostate cancer	RG7446 / atezolizumab - NSCLC AF802 (RG7853) / Alecensa (overseas) - NSCLC [1L] GA101 (RG7159) / obinutuzumab - follicular lymphoma ★ RG1273 / Perjeta - breast cancer (adjuvant) ★
Bone & Joint			ED-71 / Edirol (China) - osteoporosis NRD101 / Suvenyl (China) - knee osteoarthritis /shoulder periarthritis		

In principle, completion of first dose is regarded as the start of clinical studies in each phase.

NHL: non-Hodgkin's lymphoma HCC: hepatocellular carcinoma NSCLC: non-small cell lung cancer

SCLC: small cell lung cancer MIUC: muscle invasive urothelial carcinoma RCC: renal cell carcinoma Letters in orange: in-house projects

★: Projects with advances in stages since Jul. 27, 2017

*****: Multinational study managed by Chugai

Innovation all for the patients



Projects under Development (2) (as of Oct. 25, 2017)

Roche A member of the Roche group

	Phase I	Phase II	Phase III	Filed
Renal	EOS789 (Japan / overseas) - hyperphosphatemia			
Autoimmune	RG7845 - rheumatoid arthritis		 MRA / Actemra systemic sclerosis SA237(RG6168) / satralizumab neuromyelitis optica★ 	
CNS	RG7916 - spinal muscular atrophy		RG1450 / gantenerumab - Alzheimer's disease RG7412 / crenezumab - Alzheimer's disease	
Others	PCO371 (overseas) - hypoparathyroidism RG7716 - wAMD / DME★	RG3637 / lebrikizumab - IPF CIM331 / nemolizumab* - pruritus in dialysis patients URC102 (South Korea) - gout SKY59 (RG6107) - paroxysmal nocturnal hemoglobinuria (PI/II)	ACE910 (RG6013) / emicizumab - hemophilia A (non-inhibitor)	ACE910 (RG6013) / emicizumab (Japan / overseas) - hemophilia A (inhibitor)

In principle, completion of first dose is regarded as the start of clinical studies in each phase.

wAMD: wet age-related macular degeneration

DME: diabetic macular edema

IPF: idiopathic pulmonary fibrosis

* Atopic dermatitis is under development by licensees [Galderma (overseas) and Maruho (Japan)]

Letters in orange: in-house projects

- *: Projects with advances in stages since Jul. 27, 2017
- ★: Multinational study managed by Chugai

Development Status



Inhouse

Actemra[®]

Takayasu arteritis (TAK) and giant cell arteritis (GCA) that have not responded sufficiently to existing therapies Approved in August 2017 Giant cell arteritis

Approved in September 2017 (EU)



RG7159 / obinutuzumab

CD20-positive B-cell follicular lymphoma Filed for marketing approval in August 2017



Perjeta®

Adjuvant therapy for HER2-positive early breast cancer Filed for marketing approval in October 2017



RG7716 (Anti-VEGF/Ang2 bispecific antibody)

Wet age-related macular degeneration/diabetic macular edema Started Phase 1 study in September 2017





Actemra[®]

Other Progress (1)

CAR T cell-induced cytokine release syndrome Approved in August 2017 (US)



Alecensa®

ALK positive NSCLC [1st line] Recommendation for approval in October 2017 (EU) Priority review designation in August 2017 (US)



ACE910 / emicizumab

Hemophilia A (inhibitor) Accelerated assessment designation (EU) Priority review designation in August 2017 (US) **Other Progress (2)**

Overview of Development Pipeline





SKY59 (Anti-C5 recycling antibody)

Paroxysmal nocturnal hemoglobinuria Orphan Drug Designation in September 2017 (US)



CIM331 / nemolizumab

Prurigo nodularis Phase 2 study started by Galderma in August 2017 (overseas)



Alaglio[®] divided granules 1.5g (photodynamic diagnostic agent)

Diagnostic agent to visualize non-muscle invasive bladder cancer at the operation of its transurethral resection Approved in September 2017

Overview of Development Pipeline

Results of Clinical Trials / Publication





Perjeta[®] HER2+ advanced gastric cancer

Primary endpoint not achieved in global Phase 3 study (JACOB) Statistically significant improvement in overall survival with the addition of Perjeta to Herceptin + chemotherapy was not demonstrated



ERY974 (Anti-glipican3/CD3 bispecific antibody) Results of preclinical study published in Science Translationa

Results of preclinical study published in Science Translational Medicine in October 2017

Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)



wet Age-related Macular Degeneration (wAMD)

- The 4th largest reason for visual impairment in Japan (macular degeneration)¹⁾
- Abnormal blood vessel (neovascular vessel) growth under the retina, causing damage to the retina with a gradual reduction of visual acuity
- Prevalence of wAMD in Japanese population aged \geq 50 years is approximately 1.5% ²)

Diabetic Macular Edema (DME)

- Associated with diabetic retinopathy which is the 2nd largest reason for visual impairment in Japan ¹⁾
- Macular edema caused by increasing vascular permeability or ischemic changes due to an occlusion of retinal vessels
- Prevalence of DME in diabetic patients is approximately 7.4%³⁾

¹⁾ Health Labor Sciences Research Grant, Research for Chorioretinal or Optic nerve atrophy in 2016.

²⁾ Atarashii-Ganka 2011; 28: 25-29.

³⁾ Diabetes Care. 2012; 35: 556-64.

RG7716 and its MOA

Overview of Development Pipeline

Innovation all for the patients




Roche A member of the Roche group

RG7716

- The first human bispecific antibody for Ophthalmology diseases that selectively binds VEGF-A and Ang-2
- Modified Fc domain resulting in FcγR and FcRn deficient binding to remove platelet aggregation via Fcγ and reduce systemic exposure for improved safety ¹⁾

MOA

 Inhibits both VEGF-A, a key mediator of angiogenesis and vascular permeability, and Ang-2 (antagonist of Ang-1 which contributes to the stability of mature vessels), a destabilizer of chorioretinal vessels and inducer of vascular permeability




It is anticipated that neutralization of both VEGF-A and Ang-2 by intravitreal injection of RG7716 will improve efficacy and durability over existing anti-VEGF therapies for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME)

Innovation all for the patients

Projected Submissions (Post PoC NMEs and Products)





NSCLC: non-small cell lung cancer RCC: renal cell carcinoma SCLC: small cell lung cancer MIUC: muscle invasive urothelial carcinoma IPF: idiopathic pulmonary fibrosis

Contacts: Corporate Communications Dept.

```
Media Relations Group
```

Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607 e-mail: pr@chugai-pharm.co.jp

```
Koki Harada, Hiroshi Araki, Sachiyo Yoshimura, Chisato Miyoshi,
Yayoi Yamada
```

```
Investor Relations Group
```

```
Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607
e-mail: ir@chugai-pharm.co.jp
```

```
Toshiya Sasai, Takayuki Sakurai, Tomoko Shimizu,
Tomoyuki Shimamura
```